FDA Approved: SAXENDA — Supplemental Application (Novo Nordisk)

View source ↗

Summary

The FDA approved a supplemental application for SAXENDA (liraglutide) from Novo Nordisk. This action signifies approval of a supplemental NDA for the product.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity

Drugs mentioned

• SAXENDA (liraglutide)

Snippet

SUPPL AP for SAXENDA (LIRAGLUTIDE)